Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
P J Stiff, D Sweet, L J Kilton, C M Johnson, B Muntean, R R Blough
文献索引:Med. Pediatr. Oncol. 19(2) , 126-8, (1991)
全文:HTML全文
摘要
Sixteen patients with metastatic melanoma entered this phase II study of the efficacy of monthly cycles of Bisantrene. Toxicity was characterized by leukopenia, resulting in the hospitalization of one patient for a febrile incident, and superficial phlebitis. The results were similar to those of previous studies, in that among the 13 patients evaluable for response (six previously untreated with chemotherapy) there were no responses.
相关化合物
相关文献:
1990-01-01
[Haematologica 75(6) , 527-31, (1990)]
2014-04-29
[Clin. Cancer Res. 2(6) , 973-80, (1996)]
1998-01-20
[Bioorg. Med. Chem. Lett. 8(2) , 121-6, (1998)]
1990-08-01
[Invest. New Drugs 8(3) , 313-5, (1990)]
1993-02-01
[Leuk. Lymphoma 9(3) , 217-20, (1993)]